- Protocol Short Name and Number: COVID-19 Vaccine, 2101
- Protocol Long Name: Prospective Observational Study of The Immunogenicity of Vaccines for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) after Autologous Hematopoietic Stem Cell Transplantation (HCT), Allogeneic HCT, and Chimeric Antigen Receptor T-Cell Therapy
- Study Plan v5.0 (PDF)
- Study Plan List of Changes from v4.0 to v5.0
- Study Plan Appendices (.zip)
- ICFs (.zip)
- FAQs v6.0 (PDF)
- CIBMTR Data Reporting Guidelines v1.0
- COVID Observational Study Vaccine Flyer Template v1.0
- Site Roster Template v3.0
- Research Sample Information Guide v6.0
- LabCorp PSC Appointment Form - Fillable v3.0
- Kit Order Form – Fillable
- CIBMTR SC21-07_BMT CTN 2101_Site_Training_Attestation_Log_v1.0.docx
- CIBMTR BMT CTN Vaccine Study Overview Slides with Recording 20210412
- BMT CTN 2101 PI Call Recording - August 25, 2021
- Key Personnel
- BMT CTN # 2101 Co-Chair: Joshua Hill, MD
- BMT CTN # 2101 Co-Chair: Miguel-Angel Perales, MD
- BMT CTN # 2101 Co-Chair: Marcie Riches, MD, MS
- BMT CTN # 2101 Protocol Officer: Mary Horowitz, MD, MS, MACP
- BMT CTN # 2101 Protocol Coordinator: Megan Scott; bmtctn2101@emmes.com
- Keywords: Vaccine, Vaccination, COVID, SARS-CoV-2, Autologous Transplant, Auto Transplant, Auto, Allogeneic Transplant, Allo Transplant, Allo, CAR-T, CAR T, CART, Hematopoietic Cell Transplant, HCT, HSCT, Pediatric, Child, Children, Teen, Adolescent
Additional Result(s)
https://pubmed.ncbi.nlm.nih.gov/38801746/